Literature DB >> 27078502

Costunolide Induces Apoptosis through Generation of ROS and Activation of P53 in Human Esophageal Cancer Eca-109 Cells.

Peiyan Hua1, Mei Sun2, Guangxin Zhang1, Yifan Zhang1, Ge Song1, Zhenyu Liu3, Xin Li4, Xingyi Zhang1, Bingjin Li5.   

Abstract

Costunolide is a sesquiterpene lactone, which possesses potent anti-cancer properties. However, there is little report about its effects on esophageal cancer. In our study, we investigated the effects of costunolide on the cell viability, cell cycle, and apoptosis in human esophageal cancer Eca-109 cells. It was found that costunolide inhibited the growth of Eca-109 cells in a dose-dependent manner, which was associated with the loss of mitochondrial membrane potential (Δψm ) and the production of ROS. Costunolide induced apoptosis of Eca-109 cells as well as cell cycle arrest in G1/S phase by upregulation of P53 and P21. Costunolide triggered apoptosis in esophageal cancer cells via the upregulation of Bax, downregulation of Bcl-2, and significant activation of caspase-3 and poly ADP-ribose polymerase. These effects were markedly abrogated when cells were pretreated with N-acetylcysteine, a specific reactive oxygen specie inhibitor. These results suggest that costunolide is a potential candidate for the treatment of esophageal cancer.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Apoptosis; Costunolide; G1/S Phase; ROS; Sophageal Cancer

Mesh:

Substances:

Year:  2016        PMID: 27078502     DOI: 10.1002/jbt.21810

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  8 in total

1.  Tumor necrosis factor receptor-associated protein 1 regulates hypoxia-induced apoptosis through a mitochondria-dependent pathway mediated by cytochrome c oxidase subunit II.

Authors:  Fei Xiang; Si-Yuan Ma; Yan-Ling Lv; Dong-Xia Zhang; Hua-Pei Song; Yue-Sheng Huang
Journal:  Burns Trauma       Date:  2019-05-23

2.  Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2.

Authors:  Dujing Ban; Shangbo Hua; Wen Zhang; Chao Shen; Xuehua Miao; Wensheng Liu
Journal:  Cell Mol Biol Lett       Date:  2019-08-14       Impact factor: 5.787

Review 3.  Function of p21 and its therapeutic effects in esophageal cancer.

Authors:  Lei Wang; Huiqiong Han; Lin Dong; Zehua Wang; Yanru Qin
Journal:  Oncol Lett       Date:  2020-12-20       Impact factor: 2.967

4.  Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo.

Authors:  Hai Huang; Song Park; Haibo Zhang; Sijun Park; Wookbong Kwon; Enugyung Kim; Xiujuan Zhang; Soyoung Jang; Duhak Yoon; Seong-Kyoon Choi; Jun-Koo Yi; Sung-Hyun Kim; Zigang Dong; Mee-Hyun Lee; Zaeyoung Ryoo; Myoung Ok Kim
Journal:  J Exp Clin Cancer Res       Date:  2021-03-30

5.  Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels.

Authors:  Xia Ying Cui; Sun Hyang Park; Woo Hyun Park
Journal:  Molecules       Date:  2022-08-15       Impact factor: 4.927

6.  2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino) phenyl carbamoylsulfanyl] propionic acid, a glutathione reductase inhibitor, induces G2/M cell cycle arrest through generation of thiol oxidative stress in human esophageal cancer cells.

Authors:  Xia Li; Zhiming Jiang; Jianguo Feng; Xiaoying Zhang; Junzhou Wu; Wei Chen
Journal:  Oncotarget       Date:  2017-06-27

7.  DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells.

Authors:  Ha Si; Ba Genna; Xiangjin Zhuang; Jing Wang; B Burenbatu; Qiyu Feng; Hongyang Wang
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

8.  Costunolide Induces Autophagy and Apoptosis by Activating ROS/MAPK Signaling Pathways in Renal Cell Carcinoma.

Authors:  Dian Fu; Ding Wu; Wen Cheng; Jianping Gao; Zhengyu Zhang; Jingping Ge; Wenquan Zhou; Zhenyu Xu
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.